"Prospects do not look good. The biotechnology company Crucell N.V. and Aventis Pasteur S.A. are seeking approval from the U.S. Food and Drug Administration to introduce PER-C6, a cell strain made from a fetus aborted at eighteen weeks. Even more disconcerting are the efforts of biotechnology companies to produce new drugs and therapies from embryonic stem cells. Some U.S. states have recently passed laws encouraging this research. Any new products made from these strains will be even more controversial than the implicated vaccines."